Drug Profile


Alternative Names: KB 3022; KBT 3022; TO 192

Latest Information Update: 20 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nippon Organon; Torii Pharmaceutical
  • Class Antiplatelets; Pyrroles; Small molecules; Thiazoles
  • Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase inhibitors; Thromboxane A2 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Arterial occlusive disorders

Most Recent Events

  • 16 Nov 1999 Kanebo's pharmaceutical business has been merged with Organon's Japanese operations to form Nippon Organon
  • 25 Mar 1998 Preregistration for Arterial occlusive disorders in Japan (PO)
  • 05 Dec 1997 Three studies have been added to the adverse events and Thromboses therapeutic trials sections ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top